申请人:ICN Pharmaceuticals, Inc.
公开号:US20020095033A1
公开(公告)日:2002-07-18
Novel monocyclic L-Nucleoside compounds have the general formula
1
Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.
新型单环L-核苷化合物具有一般式1。这些化合物的实施被认为对治疗各种疾病有用,包括感染、寄生虫感染、肿瘤和自身免疫性疾病。从机理上看,这些新化合物的实施显示出免疫调节活性,并有望用于调节细胞因子模式,包括调节Th1和Th2反应。